Dechra will market the product, indicated to treat anemia in dogs, in 60 mL single dose and 125 mL single dose infusion bags.
“We look forward to mutual success with Dechra to have Oxyglobin reach its market potential,” said Barry Scott, vice president for Business Development of Biopure. “We selected Dechra because it has been successful at developing its presence in the U.S. veterinary market with FDA approved products for companion animals.”
Biopure is based in Cambridge, Mass. Dechra Veterinary Products, a division of Dechra Pharmaceuticals PLC, is based in Overland Park, Kan.